Previous 10 |
This year was another crucial one for biotech thanks in large part to initial public offerings (IPOs), merger and acquisition (M&A) activity and niche therapeutic areas garnering attention. During the year, while the number of IPOs slowed in comparison to last year, some of the largest M...
Viela Bio (NASDAQ: VIE ) doses the first patient in its Phase 2b trial of VIB4920 for the treatment of Sjögren’s syndrome. More news on: Viela Bio, Inc., Healthcare stocks news, Read more ...
GAITHERSBURG, Md., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Viela Bio (Nasdaq:VIE), a clinical-stage biotechnology company pioneering treatments for autoimmune and severe inflammatory diseases, today announced that the first patient has been dosed in a Phase 2b trial of VIB4920 for the treatment o...
News, Short Squeeze, Breakout and More Instantly...
> A three-year partnership that aligns with Veolia’s mission to support organizations and industries that want to become more environmentally sustainable > Veolia will start with focusing on improving waste collection, increasing recycling percentages, providing sustainable w...
Clean Earth will partner with Veolia North America on a five-year agreement to provide guaranteed incineration capacity in a new state-of-the-art waste treatment facility in Gum Springs, Ark. The agreement provides reliable, predictable, safe, and efficient waste disposal for Clean Ea...
The array will produce over 250 million kilowatt hours of electricity – enough to power 25,000 homes – and offset carbon output by 105,000 tons over the next 25 years, making it the only hazardous waste treatment facility in U.S. to be fully energy self-sufficient Veolia N...